Concord Medical Services Holdings (FRA:C2C) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Concord Medical Services Holdings Cash Conversion Cycle Related Terms
Concord Medical Services Holdings Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Medical Services Holdings Cash Conversion Cycle Chart
FRA:C2C vs CCEL, GBCS, CDIX: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Concord Medical Services Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Medical Services Holdings Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Concord Medical Services Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Concord Medical Services Holdings's Cash Conversion Cycle falls into.
Concord Medical Services Holdings Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Medical Services Holdings (FRA:C2C) has a Cash Conversion Cycle of -32.55 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Concord Medical Services Holdings and its competitors.
Is Concord Medical Services Holdings' Cash Conversion Cycle too high?
Concord Medical Services Holdings' current Cash Conversion Cycle is -32.55. Overall, Concord Medical Services Holdings has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Services Holdings' Cash Conversion Cycle compare to CCEL and GBCS?
Concord Medical Services Holdings' Cash Conversion Cycle of -32.55 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.91, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Concord Medical Services Holdings and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Medical Services Holdings's current Cash Conversion Cycle is -32.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Services Holdings stock overvalued right now?
Concord Medical Services Holdings (FRA:C2C) has a current Cash Conversion Cycle of -32.55. The stock's GF Value™ is €9.81, compared to a current price of €6.25 — trading 36.3% below its estimated fair value. The current Cash Conversion Cycle is -32.55. Concord Medical Services Holdings' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Concord Medical Services Holdings (FRA:C2C), the current Cash Conversion Cycle is -32.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued.
The current stock price of €6.25 is trading 36.3% below its estimated GF Value™ of €9.81.
Key valuation signals for FRA:C2C:
Cash Conversion Cycle: -32.55
GF Value™: €9.81 vs. price of €6.25 (36.3% below fair value)
No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Medical Services Holdings Business Description
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
51GF Score
Get the complete analysis for FRA:C2C
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C2C has been successfully added to your 
